While a previous observational study including 32 RRMS patients found overexpression of FGF23 in MS patients (p < 0.01) and an association of high FGF23 levels (approximately 2.5-fold higher) with comorbidities such as cardiovascular diseases in MS (33). The gene discussed is FGF23; the disease is myeloid sarcoma.